Compare MasterCard Inc (MA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? MasterCard Inc trades at $538.35 (market cap $483.71B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: MasterCard Inc is far larger — about 4× Vertex Pharmaceuticals Incorporated's market cap, and MasterCard Inc pays a 0.64% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MA | VRTX | |
|---|---|---|
Market Cap | $483.71B | $121.95B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $529.59 |
52-Week Low | $471.55 | $366.54 |
Enterprise Value | $494.45B | $116.69B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $538.30, down 0.97% on the day, with a bullish technical outlook supported by moving averages and strong price targets. The company demonstrates robust fundamentals with revenue growth from $32.79B in 2025 to a projected $33.9B in 2026, net income margins above 45%, and consistent earnings beats. Recent news highlights institutional buying and strategic initiatives in AI and financial inclusion.
The outlook remains positive given Wall Street's strong buy consensus and a $634.27 price target, though high valuation multiples and competitive disruption from new payment technologies present risks. Earnings growth and market leadership are key catalysts for upside.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
